V

ViewRay

Biotech & Life Sciences · Oakwood, United States · Founded 2004 · IPO 2015

ViewRay Inc. was a medical device company that developed and marketed advanced radiation therapy technology for cancer treatment. Founded in 2004 by James F. Dempsey, a board-certified medical physicist and former professor, the company originated from technology he invented while at the University of Florida. ViewRay's core business revolved around the design, manufacturing, and sale of its MRIdian system, which was the first device to combine a linear accelerator for radiation delivery with simultaneous magnetic resonance imaging (MRI) guidance. The company's business model focused on selling these high-capital equipment systems to hospitals, cancer centers, and government institutions worldwide. Revenue was generated from the sale of the MRIdian systems and likely through associated service and software contracts. The key product, MRIdian, aimed to resolve limitations in traditional radiotherapy by providing real-time, high-contrast soft-tissue imaging during treatment. This allowed clinicians to see the tumor and surrounding healthy organs, track tumor motion in real-time, and adapt the radiation plan as needed, a process known as adaptive radiotherapy. The primary benefit was the ability to deliver higher, more precise doses of radiation directly to the tumor while minimizing exposure to adjacent healthy tissue, potentially improving outcomes for cancers that are hard to treat or move during treatment, such as those in the pancreas, liver, and lungs. Despite developing this technology, ViewRay faced persistent financial challenges. The company had negative cash flows since its inception and accumulated significant debt. In July 2023, citing pressures from inflation, supply chain disruptions, and payment delays, ViewRay filed for Chapter 11 bankruptcy protection. The company intended to sell its assets to continue supporting existing customers. However, a buyer could not be secured, and in October 2023, ViewRay announced it would cease all operations, including service, support, and manufacturing for the MRIdian systems. Keywords: MRI-guided radiotherapy, MR-linac, adaptive radiation therapy, stereotactic body radiation therapy, radiation oncology, medical device, cancer treatment, linac, James F. Dempsey, MRIdian system, real-time tumor tracking, soft-tissue imaging, ablative doses, ViewRay bankruptcy, image-guided radiation therapy, IGRT, SBRT, oncology technology, precision radiotherapy, motion management